Promises and potential pitfalls of in vivo CAR gene therapy.
In vivo CAR gene therapy shows promising clinical proof of concept with potential to overcome ex vivo manufacturing limitations.
- Why it matters: Current ex vivo CAR T cell therapies are effective but face logistical challenges that restrict patient access, highlighting the need for alternative delivery methods.
- What they did: The study reviews recent clinical evidence and discusses technical, biological, and safety considerations of generating CAR-expressing T cells directly within the body.
- The result: In vivo approaches could expand access to CAR T cell therapy and improve safety, but require careful evaluation of their technical and biological challenges.